Overview

Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy

Status:
Terminated
Trial end date:
2018-12-17
Target enrollment:
Participant gender:
Summary
The intent of the study is to assess the antitumor activity of PHA-848125AC in patients with recurrent or metastatic, unresectable malignant thymoma previously treated with multiple lines of chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Tiziana Life Sciences, PLC
Treatments:
Maleic acid